<DOC>
	<DOCNO>NCT02543710</DOCNO>
	<brief_summary>MoMaTEC2 aim test , clinically orient study , applicability already identify promise molecular biomarkers , promote individualisation treatment patient endometrial cancer . Predominantly , exclusively , biomarkers show interesting retrospective analysis large prospectively collect MoMaTEC1 series . Part 1 : Performance phase 4 implementation trial optimise stratification surgical treatment , specifically performance ( para-aortic pelvic ) lymphadenectomy guide validated biomarkers . Part 2 : Performance phase 2b clinical biomarker study evaluate predictive potential biomarker stathmin taxane treatment response endometrial ovarian cancer . In study stathmin use integrated biomarker .</brief_summary>
	<brief_title>Biomarker Guided Treatment Gynaecological Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Inclusion Criteria part 1 : All patient refer participate research centre suspicion confirm endometrial cancer . Exclusion Criteria part 1 : 1 . Patients endometrial cancer 2 . Patients give inform consent ( include language barrier ) 3 . Patients &lt; 18 year age 4 . Patients get surgical treatment endometrial cancer Inclusion criterion part 2 : 1 . Patients endometrial epithelial ovarian cancer follow routine clinical guideline offer weekly taxane ( paclitaxel ) treatment . This often third fourth line treatment , i.e . patient advanced disease . 2 . Technical possibility obtain new tissue biopsy determine stathmin level tumour recurrence . Exclusion criterion part 2 : 1 . Patients suffer endometrial epithelial ovarian cancer 2 . Patients &lt; 18 year age 3 . Patients agree propose treatment receive ( part ) treatment nonparticipating centre 4 . Patients want give inform consent ( include language barrier )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>